← Back to screener

BIOGEN INC. BIIB

Rank #1133 · Nasdaq · $37.4B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
53.2
P/E
32.2
P/B
2.80
ROE
8.7%
Op. Margin
–%
Debt Ratio
85%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★★☆☆
Average

P/E 32.2x, P/B 2.80x. Ranks in the top 45% of the universe.

Profitability ★★☆☆☆
Average

ROE 8.7%. Ranks in the top 50% of the universe.

Safety ★★★☆☆
Good

Debt ratio 85%. Ranks in the top 34% of the universe.

Growth ★☆☆☆☆
Weak

Revenue decline of 3.3% year over year. Ranks in the top 73% of the universe.

Valuation is the relative strength · Growth is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$4.4B$1.3B$1.0B$5.4B29.649
2012$4.7B$1.2B$1.0B$6.4B26.541
2013$5.0B$1.7B$1.2B$7.0B34.245
2014$5.5B$1.9B$1.4B$8.6B33.638
2015$6.9B$2.5B$1.9B$10.8B36.332
2016$9.7B$4.0B$2.9B$8.6B40.9118
2017$10.8B$4.9B$3.5B$10.8B45.499
2018$11.4B$5.2B$3.7B$9.4B45.0118
2019$12.3B$5.3B$2.5B$12.1B43.6101
2020$13.5B$5.9B$4.4B$13.3B43.8104
2021$14.4B$7.0B$5.9B$10.7B49.0130
2022$13.4B–$4.0B$10.9B–119
2023$11.0B–$1.6B$13.4B–83
2024$10.2B–$3.0B$11.0B–110
2025$9.8B–$1.2B$13.4B–85

← See the full screener